Full Breakdown
Former Senator Ben Sasse Reports Tumor Reduction While on Experimental Pancreatic-Cancer Drug Daraxonrasib
4/29/2026, 10:50:52 AM
The Experimental Treatment and Reported Outcomes
Former U.S. Senator Ben Sasse, 54, disclosed that after a stage 4 pancreatic-cancer diagnosis in December 2025 he entered a clinical trial of daraxonrasib, an oral agent that targets the RAS growth switch. In a recent “60 Minutes” interview he said his pain has markedly decreased and that imaging shows a 76 percent reduction in tumor volume over the preceding four months.
Clinical Context and Trial Data
Daraxonrasib is being developed by Revolution Medicines, a California-based company. In a phase 3 trial of patients with metastatic pancreatic cancer who had progressed after standard chemotherapy, the drug produced a median overall survival of 13 months compared with roughly six months for those who continued chemotherapy alone. Early data also suggest that when combined with first-line chemotherapy, daraxonrasib yields greater tumor shrinkage at six months than chemotherapy alone.
Key Participants and Organizations
- Ben Sasse – former Republican senator from Nebraska, trial participant.
- Revolution Medicines – developer of daraxonrasib.
- Dr. Sarbajit Mukherjee – chief of gastrointestinal medical oncology at Miami Cancer Institute, Baptist Health South Florida, and trial commentator.
- Dr. Marc Siegel – Fox News senior medical analyst, providing background on pancreatic-cancer diagnosis.
Quantitative Findings
- Tumor volume reduction reported by Sasse: 76 % over four months.
- Phase 3 trial median survival: 13 months (daraxonrasib) vs ?6 months (chemotherapy).
- Common adverse events in the trial: rash, diarrhea, mouth sores, fatigue; managed by dose adjustments or supportive medication.
Official Statements & Responses
Revolution Medicines highlighted the trial’s survival benefit, describing daraxonrasib as “the first targeted pill in this disease that truly feels like a step change.” Dr. Mukherjee explained that the drug binds active-state RAS, “turning down” the growth signal that drives pancreatic-cancer proliferation. Dr. Siegel noted that pancreatic cancer is often diagnosed late because early symptoms are subtle, underscoring the need for targeted therapies. Sasse attributed his improved condition to “providence, prayer and a miracle drug,” while acknowledging that the medication is not yet FDA-approved and is not a cure.
Criticism, Limitations, and Safety Concerns
The drug remains investigational; it has not received FDA approval. Reported side effects require regular blood monitoring and may necessitate dose modifications. Dr. Mukherjee cautioned that “most cancers will eventually find ways to grow around the drug,” emphasizing that long-term efficacy is uncertain. The therapy is currently positioned for patients whose disease progresses after standard chemotherapy.
Discrepancies and Unresolved Questions
Sasse suggested he may live “a year instead of a handful of months,” a personal estimate that exceeds the trial’s median survival figure. No independent imaging verification of his tumor reduction is provided in the sources. The timeline for potential regulatory approval remains unspecified.
Direct Voices
- “I have much, much less pain than I had four months ago when I was diagnosed, and I have a massive 76 percent reduction in tumor volume over the last four months.” — Ben Sasse, former U.S. senator
- “From my perspective, as someone who treats pancreatic cancer every day, daraxonrasib is the first targeted pill in this disease that truly feels like a step change rather than a small incremental improvement.” — Dr. Sarbajit Mukherjee, MD
- “The limitations are important to be transparent about — it is still not yet FDA-approved, and it is not a cure.” — Dr. Sarbajit Mukherjee, MD
- “I am a literal Calvinist Christian who believes deeply in my theology. I don't want the state to constrain theology at all because I don't want it to compel or prohibit.” — Ben Sasse
- “Me getting a cancer diagnosis … is pretty small on the grand scheme of things, but it's a touch of grace because it forces me to tell the truth.” — Ben Sasse
Prospects and Ongoing Research
Current trials are evaluating daraxonrasib in combination with chemotherapy as an initial treatment regimen. If forthcoming studies confirm safety and efficacy, the drug could become a standard option after chemotherapy failure or potentially move earlier in the treatment algorithm. Sasse remains enrolled in the trial while continuing to monitor his condition.
